Gregory Y.H. Lip-rekin lankidetzan egindako argitalpenak (225)

2025

  1. A comparative analysis of HAS-BLED, ORBIT, DOAC, and AF-BLEED bleeding-risk scores in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia atrial fibrillation project III (MAFP-III) cohort

    Journal of Thrombosis and Haemostasis

  2. Cardiovascular-kidney-metabolic domains and impact on antithrombotic treatment, integrated care and clinical outcomes in patients with atrial fibrillation: results from a prospective European registry

    European Journal of Internal Medicine

  3. Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification

    Clinical Cardiology, Vol. 48, Núm. 8

  4. Frailty increases the risk of hospitalization for atrial fibrillation in older adults: a population-based cohort study

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 35, Núm. 11

  5. Optimal Medical Therapy for Heart Failure and Integrated Care in Patients With Atrial Fibrillation: A Report From the ESC-EHRA EORP Atrial Fibrillation Long-Term General Registry

    Journal of the American Heart Association, Vol. 14, Núm. 1, pp. e030499

  6. Physical activity in patients with atrial fibrillation and adverse outcomes: results from a large-scale prospective multicenter European cohort

    Revista Espanola de Cardiologia

  7. Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation

    Journal of Nutrition, Health and Aging, Vol. 29, Núm. 1

  8. Relation of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio to residual risk in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF Project III cohort

    Cardiovascular Diabetology, Vol. 24, Núm. 1

  9. Remnant–to–LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study

    Cardiovascular Diabetology, Vol. 24, Núm. 1

  10. The Neutrophil-to-Lymphocyte Ratio Is an Independent Inflammatory Biomarker for Adverse Events in Patients With Atrial Fibrillation: Insights From the Murcia AF Project II (MAFP-II) Cohort Study

    Clinical cardiology, Vol. 48, Núm. 2, pp. e70102

  11. The triglyceride-glucose index, a marker of insulin resistance, as a predictor of thrombotic risk in atrial fibrillation

    Cardiovascular Diabetology, Vol. 24, Núm. 1

2024

  1. Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 835-842

  2. Endothelial activation, Cell-Cell Interactions, and Inflammatory Pathways in Postoperative Atrial Fibrillation Following Cardiac Surgery.

    Biomedical Journal, pp. 100821

  3. Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 656-666

2023

  1. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  2. Clinical implications of different types of dementia in patients with atrial fibrillation: Insights from a global federated health network analysis

    Clinical Cardiology, Vol. 46, Núm. 6, pp. 656-662

  3. Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 25, Núm. 2, pp. 277-282

  4. Factors Associated with Progression of Atrial Fibrillation and Impact on All-Cause Mortality in a Cohort of European Patients

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  5. Ibrutinib use and adverse cardiovascular outcomes: A United States federated electronic medical records analysis

    European Journal of Internal Medicine

  6. Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making

    American Heart Journal, Vol. 258, pp. 1-16